spacer
home > ebr > winter 2018 > constant vigilance
PUBLICATIONS
European Biopharmaceutical Review

Constant Vigilance

Wirelessly connected medical devices for monitoring and treating a wide range of illnesses are proliferating. Currently, about 450,000 programmable cardiac pacemakers are implanted in patients, and devices for monitoring and treating conditions including diabetes and sleep apnea are rapidly entering the market (1).

While such network-connected devices have the power to transform patient care by enabling real time monitoring and treatment adjustment, they also present new cybersecurity risks. These range from general malware threats that affect all kinds of computers, routers and smart devices to specifically targeting medical devices to access healthcare computer networks or to hijack the devices themselves.

All of these cybersecurity threats could lead to patient injury or death by disrupting device function, whether intentionally or not. They also may inflict financial damage on product sponsors, prescribing providers and patient users in several ways. To compound the problem, cybersecurity threats constantly change, challenging sponsors and users to keep up with new and ever more sophisticated attacks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tony Clarke is Head of Information Security at ICON. Over the last 17 years, he has provided security services to numerous organisations across a number of industries,including life sciences, financial services, utilities, government bodies and EU agencies. Tony holds an MSc in security and forensic computing and numerous cybersecurity certifications. He is currently the open web application security project Dublin Chapter lead. Tony has presented at many security conferences and lectures in ethical hacking on the Dublin Institute of Technology MSc programme.


spacer
Tony Clarke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement